Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives
Metrics: PDF 240 views | Full Text 482 views | ?
Christopher J. Hanley1 and Gareth J. Thomas1,2
1 School of Cancer Sciences, University of Southampton, Southampton, UK
2 Cancer Research UK and NIHR Southampton Experimental Cancer Medicine Centre, Southampton, UK
|Gareth J. Thomas,||email:||G.Thomas@soton.ac.uk|
Keywords: tumour microenvironment; cancer associated fibroblasts; immunotherapy
Received: March 23, 2021 Accepted: March 24, 2021 Published: July 06, 2021
Cancer associated fibroblasts are a prominent component of the tumour microenvironment in most solid cancers. This heterogeneous population of cells are known to play an important role in tumour progression and recent studies have demonstrated that CAFs may confer resistance to checkpoint immunotherapy, suggesting that targeting these cells could improve response rates. However, effective clinical strategies for CAF targeting have yet to be identified. In this editorial, we highlight current limitations in our understanding of CAF heterogeneity, and discuss the potential and possible approaches for CAF-directed therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.